Imaging in 2020-7: Bridging Molecular Imaging and Therapy

描述(由申请人提供)：1998年，越来越明显的是，在生物分子成像对临床应用的未来影响方面，临床医生、生物学家、工程师和化学家之间存在着巨大的鸿沟。作为NCI和加州理工学院合作的结果，2020年成像技术的建立是为了弥合这一鸿沟。该提案要求部分支持2020年第七届成像大会。会议的形式模仿了非常成功的戈登研究会议，一个由大约100名研究人员组成的亲密小组，从临床医生到基础科学家，聚集在一起，为期4.5天，解决分子成像面临的一些最紧迫的问题及其在征服癌症中的作用。2020年的总体目标是促进这种交流，为聚集来自不同学科的如此多的研究人员奠定技术基础，并提供一种故意比传统科学会议更宽松的形式，允许在一个随意、舒适的环境中进行广泛、有意义的互动。我们希望促进持久协会的发展，这将导致创新的解决方案和应用。2020年成像的明确目标之一是将来自不同背景的研究人员聚集在一起。这些人通常不会在他们通常参加的专业会议上互动。自1999年以来，2020年的成像在促进思想和概念的交叉培养以及在主题领域和跨机构的地理位置上产生新的合作方面有着良好的记录。通常情况下，有24-26名发言者(没有并发会议)，他们的发言有固定的时间限制。讨论时间与演讲时间相同，这种形式鼓励新的合作。例如，在1999年的第一次会议上，来自7个不同机构和5个部门的几名研究人员建立了后来的分子成像学会。在很短的时间内，这个协会号称拥有1000多名成员，代表临床到临床前的研究人员，以及来自化学、生物和工程的基础科学家。 与公共健康相关：2011年，2020年的成像将探索分子成像和治疗之间的新联系。成像--尤其是分子成像--将在创建、监测和控制新的、高度有效的干预措施方面发挥关键作用。随着RNA干扰、纳米治疗和干细胞等新的治疗技术进入临床，人们越来越需要分子成像来进行设计、优化和验证。讨论将涉及从MRI到PET的成像方式的进展，光学和超声成像，重要治疗的基本进展以及化学在成像中的未来作用。

DESCRIPTION (provided by applicant): In 1998 it was becoming increasing clear that a significant gulf existed between clinicians, biologists, engineers and chemists with regard to the future impact of biological molecular imaging on clinical applications. As a result of a partnership between the NCI and the California Institute of Technology, Imaging in 2020 was established to bridge this gulf. This proposal requests partial support for the 7th Imaging in 2020 gathering. The format of the meeting was modeled after the highly successful Gordon Research Conferences where an intimate group of approximately 100 researchers from clinicians to basic scientists assemble for 4.5 days to tackle some of the most pressing issues facing molecular imaging and its role in conquering cancer. The overall goal of Imaging in 2020 is to catalyze this communication by laying the technical foundation for assembling so many investigators from varying disciplines and by providing a format that is intentionally less structured than the traditional scientific meeting, allowing for extensive, meaningful interactions in a casual, comfortable environment. We hope to foster the development of enduring associations that will lead to innovative solutions and applications. One of the explicit goals of Imaging in 2020 is to bring together investigators from diverse backgrounds. These individuals would not normally interact at the professional meetings that they typically attend. Since 1999, Imaging in 2020 has a proven track record of stimulating cross-fertilization of ideas and concepts, and generating new collaborations across subject matter areas as well as geographical across institutions. Typically, there are 24-26 speakers (no concurrent sessions) with set time limits for their presentations. The discussion time is equal to the presentation time and this format encourages new collaborations. For example, at the first meeting in 1999, several investigators from 7 different institutions and 5 departments founded the basis of what became the Society of Molecular Imaging. In a very short time, this society boasts more then 1000 members representing clinical to preclinical investigators, and basic scientists from chemistry, biology and engineering. PUBLIC HEALTH RELEVANCE: In 2011, Imaging in 2020 will explore new links between molecular imaging and therapy. Imaging - especially molecular imaging - will play a critical role in the creation, monitoring and control of new, highly potent interventions. With new therapeutic technologies such as RNA interference, nanotherapeutics and stem cells entering the clinic, molecular imaging is increasingly required for design, optimization and validation. Discussions will address advances in imaging modalities from MRI to PET, optical and ultrasound imaging, fundamental advances in important therapies and the future role of chemistry in imaging.